Research has revealed how disruption of the circadian clock, the body's internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and ...
Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction of recurrence in stage ...
Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301 ...
Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ...